LY 2090314
Alternative Names: GSK3 inhibitor - Eli Lilly; LY2090314Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class 3-ring heterocyclic compounds; Antineoplastics; Maleimides; Small molecules
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Pancreatic cancer
Most Recent Events
- 18 Oct 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV)
- 18 Oct 2018 Discontinued - Phase-II for Acute myeloid leukaemia (Recurrent) in USA (IV)
- 18 Oct 2018 Discontinued - Phase-II for Acute promyelocytic leukaemia (Recurrent) in USA (IV)